UY33003A - Asociaciones farmacéuticas, composiciones farmacéuticas, medicamento y método para el tratamiento de animales - Google Patents

Asociaciones farmacéuticas, composiciones farmacéuticas, medicamento y método para el tratamiento de animales

Info

Publication number
UY33003A
UY33003A UY0001033003A UY33003A UY33003A UY 33003 A UY33003 A UY 33003A UY 0001033003 A UY0001033003 A UY 0001033003A UY 33003 A UY33003 A UY 33003A UY 33003 A UY33003 A UY 33003A
Authority
UY
Uruguay
Prior art keywords
pharmaceutical
animals
treatment
associations
levamisole
Prior art date
Application number
UY0001033003A
Other languages
English (en)
Inventor
Dolivar Coracci Neto
Original Assignee
Ouro Fino Participacoes E Empreendimientos S A
Nucleo De Pesquisas Aplic S Ltda Npa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ouro Fino Participacoes E Empreendimientos S A, Nucleo De Pesquisas Aplic S Ltda Npa filed Critical Ouro Fino Participacoes E Empreendimientos S A
Publication of UY33003A publication Critical patent/UY33003A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a asociaciones farmacéuticas antihelmínticas que comprenden compuestos aromáticos yodados, tales como disofenol o nitroxinil, con otros principios activos farmacéuticos para el tratamiento de animales. Más específicamente, la presente invención se refiere a composiciones farmacéuticas que comprenden disofenol o nitroxinil con por lo menos otro principio activo antihelmìnitico seleccionado entre bencimidazoles, tiabenzadol, sales de levamisol o tetramisol, avermectinas o milbemicinas y,más preferentemente, sales de levamisol selleccionadas entre cloruro o fosfato de levamisol. La presente invención se refiere también a medicamentos y método de tratamiento de animales que comprenden tales medicamentos antihelmínticos.
UY0001033003A 2009-11-05 2010-11-04 Asociaciones farmacéuticas, composiciones farmacéuticas, medicamento y método para el tratamiento de animales UY33003A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0904365-9A BRPI0904365A2 (pt) 2009-11-05 2009-11-05 associações farmacêuticas, composições farmacêuticas, medicamento e método para o tratamento de animais

Publications (1)

Publication Number Publication Date
UY33003A true UY33003A (es) 2011-06-30

Family

ID=43969501

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033003A UY33003A (es) 2009-11-05 2010-11-04 Asociaciones farmacéuticas, composiciones farmacéuticas, medicamento y método para el tratamiento de animales

Country Status (9)

Country Link
US (1) US20120277175A1 (es)
EP (1) EP2497467A4 (es)
AR (1) AR078860A1 (es)
AU (1) AU2010314766A1 (es)
BR (1) BRPI0904365A2 (es)
MX (1) MX2012005229A (es)
UY (1) UY33003A (es)
WO (1) WO2011054068A1 (es)
ZA (1) ZA201203281B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4245765A3 (en) 2013-04-04 2024-03-20 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
BR102013031277B1 (pt) 2013-12-05 2018-10-02 Ouro Fino Participacoes E Empreendimentos S A processo para preparar uma suspensão anti-helmíntica e suspensão anti-helmíntica injetável
DK3082829T3 (da) 2013-12-17 2021-05-03 Boehringer Ingelheim Vetmedica Gmbh Sglt2-inhibitorer til behandlingen af metaboliske lidelser i kattedyr
DK3096765T3 (en) 2014-01-23 2019-03-04 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in dogs
ES2811261T3 (es) 2014-04-01 2021-03-11 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabólicos en animales equinos
WO2016046150A1 (en) 2014-09-25 2016-03-31 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
AU2016310535B2 (en) * 2015-08-27 2021-08-19 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising SGLT-2 inhibitors
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
US20210308044A1 (en) 2018-08-18 2021-10-07 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
US20230255885A1 (en) * 2018-08-18 2023-08-17 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527154B2 (en) * 1978-12-15 1983-02-17 Pitman-Moore Australia Limited Composition and process
NZ202422A (en) * 1981-11-25 1985-02-28 Ici Australia Ltd D, l-and l-2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazolium 4-cyano-2-iodo-6-nitrophenoxide and veterinary compositions
GB8331037D0 (en) * 1983-11-21 1983-12-29 May & Baker Ltd Compositions of matter
KR890000906B1 (ko) * 1986-06-28 1989-04-13 주식회사 한국미생물연구소 간질 및 소화관내 선충류 구충을 위한 니트록시닐과 레바미솔 복합주사제의 제조방법
WO1994028887A1 (en) * 1993-06-15 1994-12-22 The Australian National University Synergistic anthelmintic compositions
EP1182931B1 (en) * 1999-06-04 2005-12-28 Nufarm Limited Stable biocidal compositions
BRPI0505716B1 (pt) 2005-12-15 2016-12-20 Npa Núcleo De Pesquisas Aplic S Ltda sal orgânico de levamisol, processo de preparação do mesmo, composição farmacêutica e seu uso no combate de helmintiases
BRPI0506279B1 (pt) * 2005-12-16 2018-01-09 Npa - Núcleo De Pesquisas Aplicadas Ltda Composição sinergística de antihelmínticos e endectocidas
TW201111358A (en) * 2009-06-18 2011-04-01 Intervet Int Bv Anthelmintic agents and their use

Also Published As

Publication number Publication date
US20120277175A1 (en) 2012-11-01
AU2010314766A1 (en) 2012-06-21
BRPI0904365A2 (pt) 2011-11-16
AR078860A1 (es) 2011-12-07
WO2011054068A1 (pt) 2011-05-12
ZA201203281B (en) 2013-06-26
MX2012005229A (es) 2012-09-07
EP2497467A1 (en) 2012-09-12
EP2497467A4 (en) 2013-03-20

Similar Documents

Publication Publication Date Title
UY33003A (es) Asociaciones farmacéuticas, composiciones farmacéuticas, medicamento y método para el tratamiento de animales
MD20140093A2 (ro) Compoziţii masticabile de uz veterinar care conţin agent activ izoxazolinic şi utilizarea acestora în tratamentul sau prevenirea unei infestări sau infecţii parazitare
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
CO6710926A2 (es) Compuestos de n-heteroarilo
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
MX2011009847A (es) Agentes antihelminticos y su uso.
ECSP088102A (es) Compuestos para el tratamiento de infecciones bacterianas resistentes a múltiples fármacos
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
UY30373A1 (es) Derivados de fenilalanina, procedimientos de preparacion y aplicaciones
CL2020000747A1 (es) Formulaciones de niraparib.
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
CO6410278A2 (es) Disoluciones pediátricas que continen un beta-bloqueante
CL2013002700A1 (es) Cápsula suave ingerible que contiene inositol y excipientes, o inositol, excipientes y al menos un principio activo adicional, tal como ácido fólico, polifenoles de cocoa, genisteína, l-arginina, vitamina e, selenio, n-acetilcisteína y melatonina; útil para el tratamiento del ovario poliquístico, resistencia a la insulina y otros
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
BR112017008721A2 (pt) formulação líquida injetável, composição de liberação controlada, e, métodos para entrega prolongada de buprenorfina, para formação de uma composição de liberação controlada e para tratamento ou profilaxia de um sujeito animal humano ou não humano.
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
MX2011013869A (es) Agentes antihelminticos y su uso.
ECSP13013095A (es) Composición farmacéutica que comprende fexofenadina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190221